Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Statera Biopharma Inc

Company price
0.0001 USD 0.00(0%)
Last update at 2026-11-19T21:00:00Z
VOLUME
700
Market Cap
0.01M

Momentum Score

…

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company develops therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado. Statera Biopharma, Inc. is a subsidiary of Biostax Corp.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
0.00
Low
0.03
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Statera Biopharma Inc is a publicly traded company on the OTC Pink market that identifies as a biopharmaceutical firm; public disclosures about its pipeline, commercial products and financials are limited. Long-term value may depend on successful clinical development, regulatory approvals, strategic partnerships and access to capital, so investors may benefit if those execution milestones are achieved.
Primary risks include low liquidity typical of Pink‑sheet listings, execution and clinical/regulatory risk for development-stage programs, and the potential for financing-related dilution.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
3.69M
Revenue Per Share
0.08
Gross Profit TTM
2.59M
Debt / Equity
-10.37
ROE
-286.94%
Net Debt
14.42M
ROCE
389.74%
Diluted EPS TTM
-4.72

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -101.88M -101.88M -12.09M -3.22M -3.61M
Minority interest - 0.02M - 0.21M -
Net income -174.41M -101.85M -13.22M -3.35M -3.61M
Selling general administrative 18.41M 19.91M 5.24M 2.23M 2.32M
Selling and marketing expenses 0.08M - 0.00M - -
Gross profit -0.49M -0.49M 11.54M 15.14M 1.91M
Reconciled depreciation - 0.26M 0.00M 0.00M -
Ebit 38.68M -31.24M -10.50M -2.81M -0.99M
Ebitda 38.93M -30.49M -10.50M -2.81M -4.80M
Depreciation and amortization 0.26M - 0.00M -0.29M -
Non operating income net other - - 2.93M 1.37M 0.84M
Operating income 38.68M -30.74M -10.50M -2.81M -4.80M
Other operating expenses 29.32M - 10.50M 2.81M 5.94M
Interest expense 4.56M - 1.13M 0.12M 0.00M
Net interest income - -4.56M -1.13M -0.12M -
Income tax expense 72.53M - 1.13M 0.12M 0.29M
Total revenue 1.49M 0.00M 41.55M 47.07M 7.59M
Total operating expenses 28.83M 30.74M 10.50M 2.81M 5.94M
Cost of revenue 0.49M 0.49M 30.01M 31.93M 5.68M
Total other income expense net -140.55M -66.57M -1.59M -0.41M 1.19M
Discontinued operations - 0.00M 0.00M 0.00M -0.90M
Net income from continuing ops - -101.88M -6.76M -5.51M -1.66M
Net income applicable to common shares - -101.85M -6.76M -5.71M -2.92M
Preferred stock and other adjustments - - - - 0.36M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 21.17M 21.17M 1.04M 0.00M 4.53M
Intangible assets 1.58M 1.58M - - -
Other current assets 0.02M 0.85M 0.33M 0.05M 0.10M
Total liab 22.68M 22.68M 4.69M 4.21M 0.92M
Total stockholder equity -1.57M -1.57M -3.66M -4.21M -1.45M
Deferred long term liab - - 0.16M - 0.16M
Other current liab 2.08M 0.70M 0.14M 1.26M 0.77M
Common stock 0.18M 0.18M 0.02M 0.02M 0.06M
Capital stock - 0.18M 0.03M 0.02M -
Retained earnings -129.48M -129.48M -27.63M -15.54M -164.06M
Good will 9.27M 9.27M 4.45M 4.45M -
Other assets - 5.00M - -0.03M -
Cash 1.84M 1.84M 0.59M 0.00M 3.62M
Total current liabilities 11.25M 11.25M 4.62M 4.21M 0.91M
Current deferred revenue 0.37M - -0.14M -1.26M -
Net debt 14.42M 13.36M 1.41M 1.80M -3.62M
Short term debt 4.83M - 1.93M 1.80M 0.20M
Short long term debt - 4.58M 1.90M 1.80M -
Short long term debt total 16.26M - 2.00M 1.80M -
Other stockholder equity 127.74M -0.01M 24.63M 11.31M 163.16M
Property plant equipment - 1.17M 0.11M 60.36M 0.55M
Total current assets 4.16M 4.16M 0.93M 0.00M 4.48M
Long term investments - - 11.90M 10.52M 9.98M
Net tangible assets - -12.42M 57.58M 63.39M 11.72M
Short term investments 0.13M 0.13M 0.32M 0.45M 0.50M
Net receivables 0.35M 0.35M 0.01M 0.38M 0.25M
Long term debt - 10.62M 0.68M - -
Inventory 1.81M - -0.01M -0.42M 0.07M
Accounts payable 3.96M 3.96M 2.69M 2.41M 0.14M
Accumulated other comprehensive income -0.01M - -0.69M -0.57M -0.61M
Common stock total equity - - 0.02M 0.02M 0.01M
Retained earnings total equity - - -29.39M -22.63M -5.42M
Treasury stock - - - - -0.96M
Non currrent assets other 5.00M 5.00M 53.15M 0.03M 0.06M
Non current assets total 17.01M 17.01M 0.11M 0.03M 0.06M
Capital lease obligations - 1.06M 0.10M - -
Long term debt total - - 0.68M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments - 13.46M -0.01M 0.00M -
Change to liabilities - 1.24M -0.45M 1.93M -5.06M
Total cashflows from investing activities - 13.46M -0.26M -3.24M 9.86M
Net borrowings - 13.97M -3.19M 1.94M 1.02M
Total cash from financing activities 20.99M 20.99M 5.68M 0.23M 0.06M
Change to operating activities - 0.66M -0.33M 0.41M -0.41M
Net income -101.88M -101.85M -12.09M -3.22M -3.71M
Change in cash 6.25M 6.25M 0.59M -0.01M -0.61M
Begin period cash flow 0.59M 0.59M 0.00M 0.01M 4.23M
End period cash flow 6.84M 6.84M 0.59M 0.00M 3.62M
Total cash from operating activities -28.19M -28.19M -5.08M -0.24M -4.61M
Issuance of capital stock - 7.34M 5.75M 0.00M -
Depreciation 0.26M 0.26M 0.00M 0.01M 0.02M
Other cashflows from investing activities - - -0.06M 0.05M 0.01M
Change to inventory -1.00M -0.13M -0.05M -0.03M 0.12M
Change to account receivables -0.35M -0.42M 0.38M -0.07M 0.43M
Sale purchase of stock - - - - -0.04M
Other cashflows from financing activities -0.13M -0.33M 4.34M 0.16M 0.06M
Change to netincome - 71.92M 0.08M -1.29M -3.34M
Capital expenditures 0.18M 0.18M 0.01M 2.12M 0.26M
Change receivables - - -0.33M -0.77M 2.65M
Cash flows other operating - - -0.20M 0.51M 3.63M
Exchange rate changes - - - - -0.17M
Cash and cash equivalents changes - - -2.12M 2.81M -0.17M
Change in working capital 1.07M 1.07M -0.05M 1.11M 0.11M
Stock based compensation 6.06M 6.06M 2.70M - -
Other non cash items -1.30M -1.30M 7.06M 1.86M -1.03M
Free cash flow -28.38M -28.38M -5.09M -0.24M -4.61M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
STAB
Statera Biopharma Inc
-
-%
0.00 - - 0.00 0.16 314.42 -0.46
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Statera Biopharma Inc

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company develops therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado. Statera Biopharma, Inc. is a subsidiary of Biostax Corp.

4333 Corbett Drive,, Fort Collins, CO, United States, 80525

888 613 8802

46

Name Title Year Born
Mr. Michael Kevin Handley CEO, Pres & Chairman 1971
Mr. Christopher Zosh Exec. VP of Fin., Interim Principal Financial Officer & Interim Principal Accounting Officer 1976
Dr. Robert W. Buckheit Jr., Ph.D. Chief Technology Officer 1960
Todd Headley Exec. VP of Corp. Devel. NA
George Wagner Exec. VP of Regulatory Affairs NA
Dr. Blake Hawley D.V.M., M.B.A. Executive Chairman 1965
Mr. Christopher Zosh Executive VP of Finance, Interim Principal Financial Officer & Interim Principal Accounting Officer 1976
Dr. Robert W. Buckheit Jr., Ph.D. Chief Technology Officer 1961

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…